×
About 176,573 results

Lower bevacizumab doses, agents with less systemic exposure may be safer options for ROP
https://www.healio.com/news/ophthalmology/20220203/lower-bevacizumab-doses-agents-with-less-systemic-exposure-may-be-safer-options-for-rop

Feb 3rd, 2022 - WAIKOLOA, Hawaii — Systemic effects of anti-VEGF in retinopathy of prematurity have not been ruled out, so it may be wise to use bevacizumab in lower doses or switch to agents with less systemic exposure, according to one presenter. “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage 3+ ROP. But one thing I didn’t like was the complet...

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
https://clinicaltrials.gov/ct2/show/NCT03412565

Aug 12th, 2022 - The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected...

Impact of chemoprophylaxis on Plasmodium vivax and Plasmodium ovale infection among civ...
https://doi.org/10.1093/cid/ciac641
Clinical Infectious Diseases : an Official Publication Of... Le Goff M, Kendjo E et. al.

Aug 14th, 2022 - The impact of chemoprophylaxis targeting Plasmodium falciparum on Plasmodium vivax and Plasmodium ovale, which may remain quiescent as hypnozoites in the liver, is debated. We conducted a nested case-control analysis of the outcomes of P. vivax and P. ovale infections in imported malaria cases in France among civilian travellers from January 1st, 2006, to December 31st, 2017. Using adjusted log...

Massive intravascular hemolysis is an important factor in Clostridium perfringens-induc...
https://doi.org/10.1007/s11739-022-03036-3
Internal and Emergency Medicine; Suzaki A, Komine-Aizawa S et. al.

Aug 14th, 2022 - Clostridium perfringens bacteremia is rare but often fatal. In particular, once bacteremia with massive intravascular hemolysis (MIH) occurs, the mortality rate is extremely high. However, because of its rarity, the detailed pathophysiology of this fulminant form of bacteremia is unclear. To elucidate the detailed pathogenesis of MIH, we retrospectively reviewed the data of all patients with C....

Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC.
https://doi.org/10.1136/bcr-2022-250009
BMJ Case Reports; Cerniglia M, Klepadlo M et. al.

Aug 13th, 2022 - For hepatocellular carcinoma, the IMbrave150 trial demonstrated that combination atezolizumab and bevacizumab had significantly better overall survival compared with sorafenib in patients with unresectable disease. However, as more immune checkpoint inhibitors are approved as first-line agents in gastrointestinal cancers, there have been few reports on whether sequential PD-1/PD-L1 blockade is ...

Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention.
https://doi.org/10.1016/bs.acr.2022.02.001
Advances in Cancer Research; Cadamuro M, Strazzabosco M

Aug 13th, 2022 - Cholangiocarcinoma (CCA), a neoplasm burdened by a poor prognosis and currently lacking adequate therapeutic treatments, can originate at different levels of the biliary tree, in the intrahepatic, hilar, or extrahepatic area. The main risk factors for the development of CCA are the presence of chronic cholangiopathies of various etiology. To date, the most studied prodromal diseases of CCA are ...

Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future pos...
https://doi.org/10.1016/bs.acr.2022.01.012
Advances in Cancer Research; Høgdall D, O'Rourke CJ et. al.

Aug 13th, 2022 - A diagnosis of cholangiocarcinoma (CCA) is implicit with poor prognosis and limited treatment options, underscoring the near equivalence of incidence and mortality rates in this disease. In less than 9years from genomic identification to FDA-approval of the corresponding inhibitors, fibroblast growth factor receptor 2 (FGFR2) rearrangements and isocitrate dehydrogenase 1 (IDH1) mutations became...

Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe l...
https://doi.org/10.1177/09612033221119123
Lupus Liu D, Zhou Q et. al.

Aug 13th, 2022 - Systemic lupus erythematosus is a chronic inflammatory autoimmune disease that has various manifestations. Lupus nephritis is a common and severe presentation, which results in increased morbidity and mortality. Belimumab added on standard therapy has been proved to induce disease remission and improve renal parameters. However, the use of belimumab has not been explored in patients requiring d...

Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly pa...
https://doi.org/10.1007/s00432-022-04246-0
Journal of Cancer Research and Clinical Oncology; Samaran Q, Samaran R et. al.

Aug 13th, 2022 - Anti-PD1 agents are currently recommended as first-line treatment in advanced cutaneous squamous cell carcinoma (acSCC) by updated European guidelines. Although acSCC frequently affects elderly patients with multiple comorbidities, this subset of patients is often excluded of registration clinical trials. To assess anti-PD-1 efficacy and safety in elderly acSCC patients in real-life conditions ...

Symptom burden and immune dynamics 6 to 18 months following mild SARS-CoV-2 infection -...
https://doi.org/10.1093/cid/ciac655
Clinical Infectious Diseases : an Official Publication Of... Fjelltveit EB, Blomberg B et. al.

Aug 13th, 2022 - The burden and duration of persistent symptoms after non-severe COVID-19 remains uncertain. This study aimed to assess post-infection symptom trajectories in home-isolated COVID-19 cases compared to age- and time-period matched seronegative controls, and investigate immunological correlates of long COVID. A prospective case-control study conducted between February 28th and April 4th 2020 includ...

Hepatocytes infected with hepatitis C virus change immunological features in the liver ...
https://doi.org/10.3350/cmh.2022.0032
Clinical and Molecular Hepatology; Park SJ, Hahn YS

Aug 13th, 2022 - Hepatitis C virus (HCV) infection is remarkably efficient in establishing viral persistence, leading to the development of liver cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antiviral agents (DAA) are promising HCV therapies to clear the virus. However, recent reports indicate potential increased risk of HCC development among HCV patients with cirrhosis following DAA therapy. CD8...

Biologic Agents in Crohn's Patients Reduce CD4+ T Cells Activation and Are Inversely Re...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357708
Canadian Journal of Gastroenterology & Hepatology; Rosseto-Welter EA, D'argenio-Garcia L et. al.

Aug 13th, 2022 - Crohn's disease (CD) is a chronic inflammatory disease with a complex interface of broad factors. There are two main treatments for Chron's disease: biological therapy and nonbiological therapy. Biological agent therapy (e.g., anti-TNF) is the most frequently prescribed treatment; however, it is not universally accessible. In fact, in Brazil, many patients are only given the option of receiving...

Identifying RBBP7 as a Promising Diagnostic Biomarker for BK Virus-Associated Nephropathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357817
Journal of Immunology Research; Wang Y, Wang Y et. al.

Aug 13th, 2022 - BK virus-associated nephropathy (BKVN) remains a major infectious complication due to powerful immunosuppression in kidney transplant recipients, and its histologic appearance can mimic rejection, leading to diagnostic and treatment dilemmas thus molecular diagnostic methods would be beneficial. We collected gene expression profiles of 169 kidney biopsies taken from BKVN, rejection, and stable ...

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01896999

Aug 12th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the complete response (CR) rate for the regimens of brentuximab vedotin and nivolumab compared to brentuximab vedotin, ip...

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT01886872

Aug 12th, 2022 - PRIMARY OBJECTIVE: I. To determine whether progression free survival (PFS) is superior after therapy with bendamustine hydrochloride (bendamustine) in combination with rituximab, ibrutinib alone, or ibrutinib in combination with rituximab in patients age 65 or older with previously untreated chronic lymphocytic leukemia (CLL). SECONDARY OBJECTIVES: I. To determine 2-year PFS in each of the thre...

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treat...
https://clinicaltrials.gov/ct2/show/NCT01974440

Aug 12th, 2022 - This is a randomized (individuals assigned to study treatment by chance), double-blind (individuals and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study in approximately 400 adult participants with follicular lymphoma or marginal zone lymph...

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01829568

Aug 12th, 2022 - PRIMARY OBJECTIVE: I. To determine the recommended phase II doses of ibrutinib and lenalidomide for combination with rituximab in previously untreated follicular lymphoma. SECONDARY OBJECTIVES: I. To determine pharmacokinetics of ibrutinib and its major metabolite (PCI-45227) when combined with lenalidomide and rituximab. II. To determine the pharmacodynamics of basophil activation and Bruton t...

Statin Adjunctive Therapy for TB (StAT- TB)
https://clinicaltrials.gov/ct2/show/NCT03456102

Aug 12th, 2022 - There is an urgent need for novel therapies to shorten TB treatment and improve long-term lung function outcomes. Host-directed therapies (HDT) have received significant attention recently given the ability of M. tuberculosis to subvert host immune responses and cause destructive lung pathology. Statins are among the most promising HDT agents for TB. In addition to having a highly favorable saf...

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01979536

Aug 12th, 2022 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99). II. To estimate the event free survival (EFS) of Arm brentuximab vedotin (BV) and Arm crizotinib (CZ) and contrast these to historical...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Aug 12th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimen, with less than 30% having durable complete responses (CRs). Of the chemotherapy agents used, doxorubi...